OBJECTIVE: To assess the suitability of blood shed into the Solcotrans orthopaedic autotransfusion system as a source of autologous blood for transfusion. DESIGN: Blood samples were taken from patients after surgery and from shed blood within the Solcotrans units. SETTING: Surgery was performed at a public hospital. PATIENTS: All six patients underwent total knee replacements. MAIN OUTCOME MEASURES: Measurements were made of haemoglobin, haematocrit, platelets, pH, potassium, plasma haemoglobin, fibrinogen, D-dimer, plasminogen activator, thromboplastin and fibrinopeptide A. The non-activated partial thromboplastin time was estimated. Shed blood was compared with homologous whole blood to assess the thrombogenic potential of shed blood in vitro. RESULTS: The haemoglobin and haematocrit levels of the shed blood were significantly lower than venous blood (P = 0.008). Levels of potassium in shed blood were normal although there was significant haemolysis. Shed blood was depleted of clotting factors, with increased levels of D-dimer (16-128 g/L). Activation of the coagulation pathway within the shed blood was shown by a shortened non-activated partial thromboplastin time (90-120 s), and detectable levels of thromboplastin. Propionibacterium acnes was isolated from one of the units. CONCLUSION: Reinfusion of large volumes of shed blood should probably be avoided, but use of the Solcotrans orthopaedic transfusion system in conjunction with other autologous transfusion practices can reduce the patient's requirement for homologous blood.
OBJECTIVE: To assess the suitability of blood shed into the Solcotrans orthopaedic autotransfusion system as a source of autologous blood for transfusion. DESIGN: Blood samples were taken from patients after surgery and from shed blood within the Solcotrans units. SETTING: Surgery was performed at a public hospital. PATIENTS: All six patients underwent total knee replacements. MAIN OUTCOME MEASURES: Measurements were made of haemoglobin, haematocrit, platelets, pH, potassium, plasma haemoglobin, fibrinogen, D-dimer, plasminogen activator, thromboplastin and fibrinopeptide A. The non-activated partial thromboplastin time was estimated. Shed blood was compared with homologous whole blood to assess the thrombogenic potential of shed blood in vitro. RESULTS: The haemoglobin and haematocrit levels of the shed blood were significantly lower than venous blood (P = 0.008). Levels of potassium in shed blood were normal although there was significant haemolysis. Shed blood was depleted of clotting factors, with increased levels of D-dimer (16-128 g/L). Activation of the coagulation pathway within the shed blood was shown by a shortened non-activated partial thromboplastin time (90-120 s), and detectable levels of thromboplastin. Propionibacterium acnes was isolated from one of the units. CONCLUSION: Reinfusion of large volumes of shed blood should probably be avoided, but use of the Solcotrans orthopaedic transfusion system in conjunction with other autologous transfusion practices can reduce the patient's requirement for homologous blood.
Authors: Paolo Adravanti; Eleonora Di Salvo; Giuseppe Calafiore; Sebastiano Vasta; Aldo Ampollini; Michele Attilio Rosa Journal: Arthroplast Today Date: 2017-10-06